Ultragenyx Pharmaceutical Inc. (RARE) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Ultragenyx Pharmaceutical...

    NASDAQ: RARE · Real-Time Price · USD
    31.82
    0.54 (1.73%)
    At close: Sep 05, 2025, 3:59 PM
    31.82
    0.00%
    After-hours: Sep 05, 2025, 05:10 PM EDT

    Ultragenyx Pharmaceutical Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 560.23M 434.25M 363.33M 351.41M
    Cost of Revenue
    		 76.73M 45.21M 28.32M 16.01M
    Gross Profit
    		 483.5M 389.04M 335.01M 335.4M
    Operating Income
    		 -535.97M -569.21M -648.92M -381.74M
    Interest Income
    		 36.51M 26.69M 11.07M 1.93M
    Pretax Income
    		 -567.59M -608.46M -701.73M -452.98M
    Net Income
    		 -569.18M -606.64M -707.42M -454.02M
    Selling & General & Admin
    		 321.61M 309.8M 278.14M 219.98M
    Research & Development
    		 697.87M 648.45M 705.79M 497.15M
    Other Expenses
    		 n/a n/a 9.51M 241K
    Operating Expenses
    		 1.02B 958.25M 983.93M 717.13M
    Interest Expense
    		 63.04M 66M 43.02M 29.42M
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 1.1B 1B 1.01B 733.14M
    Income Tax Expense
    		 1.6M -1.82M 5.7M 1.04M
    Shares Outstanding (Basic)
    		 90.54M 73.54M 69.91M 67.8M
    Shares Outstanding (Diluted)
    		 90.54M 73.54M 69.91M 67.8M
    EPS (Basic)
    		 -6.29 -8.25 -10.12 -6.7
    EPS (Diluted)
    		 -6.29 -8.25 -10.12 -6.7
    EBITDA
    		 -469M -516.45M -640.51M -410.32M
    EBIT
    		 -504.55M -542.46M -658.71M -423.56M
    Depreciation & Amortization
    		 35.54M 26.01M 18.2M 13.24M

    Add to Watchlist